Biopolym. Cell. 2003; 19(1):89-92.
Trophinotropin «Cerebral» — endogenous neuroimmunoprotector and γ-interferon inducer
1Makarenko A. N., 2Rybalko S. L.
  1. Institute of Pharmacology and Toxicology of National Medical Academy of Science of Ukraine
    14, Eugene Pottier Str., Kyiv, Ukraine, 03057
  2. Gromashevsky L.V. Institute of Epidemiology and Infection Diseases, AMS of Ukraine
    5, Amosova Str., Kyiv, Ukraine, 03038


Interferon-inducing activity of «Cerebral», endogenous trophinotropin agent, controlling growth factors of CNS, has been evaluated in human blood leukocytes. «Cerebral» has been shown to induce γ-interferon at a titer of 160–320 IU/ml. Interferon-inducing activity of «Cerebral» may contribute to the correction mechanisms of immune disorders in patients with acute hemorrhagic stroke.


[1] Barolin GS, Koppi S, Kapeller E. Previous and novel approaches to stroke treatment. Metabolic active drugs using and rehabilitation outcome. Eur Rehab. 1996;3: 135-43.
[2] Mashkovskiy MD. Medicines: A Guide to pharmacotherapy for physicians. Kharkov: Torsing, 1997. vol 2:105.
[3] Xiong H, Baskys A, Wojtowicz JM. Brain-derived peptides inhibit synaptic transmission via presynaptic GABAB receptors in CA1 area of rat hippocampal slices. Brain Res. 1996;737(1-2):188-94.
[4] Benowitz L. Novel treatment in stroke. Endogenous low molecular weight factors support extensive CNS axon growth. Eur J Neuropsychopharm. 2000; 10(4, Suppl. 4. S12): 23.
[5] Dev'yatkina TO, Vazhnycha OM, Makarenko OM. Effect of extracts of the neocortex animals on the state of the blood system in post stressor period. Liki. 1999; (5-6):66-70.
[6] Kuznetsova LK, Kuznetsov OG. The influence of medication «Cerebral» on T-lymphocytes of asthma patients. 4th Int. Congr. Sona'99 (Dakar, 12-16 April, 1999). Dakar, 1999: 30.
[7] Makarenko AN, Danilenko VPh, Koroliov YuN, Kasianov SV. Vasoischemic brain pathology treatment by the SNC-TTR-Traumatrophical Neuropeptide Regulative Factor (Neurotrophinotropin). 4th Congr. Sona'99 (Dakar, 12-16 April, 1999). Dakar, 1999: 127.
[8] Maksynwv YuN, Arkadyev VG, Makarenko AN, Pustovarov AYu. Immunological action of a new Trophinotropic factor «Cerebral» (SNC-TTP) for stroke and child cerebral pulsy treatment: Proc. 8th Meet, of World Fed Neurol Acta Neurol Taiwan. 1999; 8(Suppl. 1):42.
[9] Pat Ukraine N 24299 A. Tools for treatment of stroke and how it is getting. OM Makarenko, YuN Korol'ov. Publ. 28.02.2000.
[10] Arkad'ev VG, Npvik LV, Pustovarov AYu, Maksimov YuI, Makarenko AI. Influence "Cerebral" - the new anti Stroke means the immune system in experimental hemorrhagic stroke. Eksperim klin farmakologiya. 2001; 64(4):20-4.
[11] Ho M, Enders JF. An inhibitor of viral activity appearing in infected cell cultures. Proc Natl Acad Sci U S A. 1959;45(3):385-9.
[12] Takei M, Takeda K, Konno K. The role of interferon-gamma in induction of differentiation of human myeloid leukemia cell lines, ML-1 and HL-60. Biochem Biophys Res Commun. 1984;124(1):100-5.
[13] Rand KH, Rasmussen LE, Pollard RB, Arvin A, Merigan TC. Cellular immunity and herpesvirus infections in cardiac-transplant patients. N Engl J Med. 1977;296(24):1372-7.
[14] Weimar W, Jeekel H. Deficient production of immune interferon in renal-transplant recipients. N Engl J Med. 1982;307(22):1403-7.
[15] Levin MJ, Parkman R, Oxman MN, Rappeport JM, Simpson M, Leary PL. Proliferative and interferon responses by peripheral blood mononuclear cells after bone marrow transplantation in humans. Infect Immun. 1978;20(3):678-84.
[16] Epstein L, Cline MJ. Chronic lymphocytic leukaemia. Studies on mitogen-stimulated lymphocyte interferon as a new technique for assessing T lymphocyte effector function. Clin Exp Immunol. 1974;16(4):553-63.
[17] Epstein LB, Ammann AJ. Evaluation of T lymphocyte effector function in immunodeficiency diseases: abnormality in mitogen-stimulated interferon in patients with selective IgA deficiency. J Immunol. 1974;112(2):617-26.
[18] Starr SE, Tolpin MD, Friedman HM, Paucker K, Plotkin SA. Impaired cellular immunity to cytomegalovirus in congenitally infected children and their mothers. J Infect Dis. 1979;140(4):500-5.
[19] Buimovici-Klein E, Lang PB, Ziring PR, Cooper LZ. Impaired cell-mediated immune response in patients with congenital rubella: correlation with gestational age at time of infection. Pediatrics. 1979;64(5):620-6.
[20] Vervliet G, Carton H, Billiau A. Interferon-gamma production by peripheral blood leucocytes from patients with multiple sclerosis and other neurological diseases. Clin Exp Immunol. 1985;59(2):391-7.
[21] Hart CC, Murray HW. Cellular immunity and the acquired immune deficiency syndrome: failure to secrete lymphokines and gamma interferon. Surv Synth Pathol Res. 1984;3(5):397-408.